Effects of Serelaxin in Patients with Acute Heart Failure

Metra, Marco; R. Teerlink, John; Cotter, Gad; A. Davison, Beth; Michael Felker, G.; Filippatos, Gerasimos; Greenberg, Barry; S. Pang, Peter; Ponikowski, Piotr; A. Voors, Adriaan; F. Adams, Kirkwood; D. Anker, Stefan; Arias‐Mendoza, Alexandra; Avendaño, Patricio; Bacal, Fernando; Böhm, Michael; Bortman, Guillermo; G.F. Cleland, John; Cohen‐Solal, Alain; G. Crespo‐Leiro, María; Dorobanţu, Maria; Eduardo Echeverría, Luis; Ferrari, Roberto; Goland, Sorel; Gonçalvesová, Eva; Goudev, Assen; Køber, Lars; Lema-Osores, Juan; D. Levy, Phillip; McDonald, Kenneth; Manga, Pravin; Merkely, Béla; Mueller, Christian; Pieske, Burkert; Silva‐Cardoso, José; Špinar, Jindřich; Squire, Iain; Stępińska, Janina; Van Mieghem, W.; von Lewinski, Dirk; Wikström, Gerhard; Birhan Yılmaz, Mehmet; Hagner, Nicole; Holbro, Thomas; A. Hua, Tsushung; V. Sabarwal, Shalini; Severin, Thomas; Szecsödy, Peter; Gimpelewicz, Claudio

doi:10.1056/nejmoa1801291

Public

Effects of Serelaxin in Patients with Acute Heart Failure

Published in New England Journal of Medicine • Aug 21, 2019

Authors:

Marco Metra

John R. Teerlink

Gad Cotter

Abstract

BACKGROUND: Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acut...

Subject

Heart failure

Medicine

Intensive care medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!